Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Sherman Oaks, California Clinical Trials

A listing of Sherman Oaks, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (9) clinical trials

Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis.

The main purpose of this study is to characterize the long-term safety and efficacy of the drug BMS-986165 in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.

Phase

0.56 miles

Learn More »

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

PRIMARY OBJECTIVES: I. To evaluate whether progression-free survival (PFS) meets an efficacy threshold in patients with previously treated advanced small bowel adenocarcinoma who receive treatment with ramucirumab and paclitaxel or FOLFIRI. II. If the stated threshold is met in both arms, to choose the better regimen with respect to progression …

Phase

5.3 miles

Learn More »

The Pharmacokinetics Safety and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

This study will examine the pharmacokinetics (PK), safety, and tolerability of fixed-dose combination abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) dispersible and immediate release tablets in HIV-1-infected children less than 12 years of age. Children will be enrolled into one of five ABC/DTG/3TC dosing groups based on their weight. The first 5-7 children …

Phase

5.45 miles

Learn More »

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

This is an open-label study evaluating the safety and efficacy of CP101 treatment in 1) Subjects in CDI-001 who had a CDI recurrence within 8 weeks of receiving CP101 or placebo; OR 2) adults with recurrent CDI who are eligible for direct study entry into CP101-CDI-E02. Subjects who are experiencing …

Phase

5.45 miles

Learn More »

Testing of a Navigation Intervention for Hepatitis C and HIV

Hepatitis C (HCV) is the most common chronic, blood-borne infection in the U.S. and, untreated, can result in liver failure and liver cancer. Despite advances in treatment and remarkable improvements in cure rates, very few persons with chronic HCV infection are receiving this treatment, especially among people who use drugs, …

Phase N/A

5.99 miles

Learn More »

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug Atezolizumab to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

PRIMARY OBJECTIVES: I. To select the better docetaxel-based experimental arm to improve disease-free survival (DFS) over the control arm of radiation and cisplatin. (Phase II) (COMPLETE AS OF 20-MAR-2020) II. To determine if the combination of docetaxel-cetuximab and intensity-modulated radiation therapy (IMRT) is superior in terms of overall survival (OS) …

Phase

6.41 miles

Learn More »

Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy

The purpose of this study is to examine the usefulness of implanting small 24-K gold fiducial markers around a bladder tumor site, so that a Radiation Oncologist can identify the original tumor location at the time of radiation treatment. Other goals of the study include assessing whether a new MRI …

Phase N/A

6.86 miles

Learn More »

Effects of Fast Bar on Physiological Fasting

Interest in fasting-based programs (i.e. intermittent fasting) for improvement of health and longevity continues to grow. While benefits of intermittent fasting have been convincingly demonstrated in rodent models, the more limited data in humans is less clear. The short-term fasting (e.g. 12 to 48 hours in duration) utilized in many …

Phase N/A

6.86 miles

Learn More »

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

AMXI-5001 is a dual PARP (poly adenosine diphosphate [ADP] ribose polymerase) and microtubule polymerization inhibitor. ATLAS-101 is a Phase I/II, open label, multi-center, non-randomized dose escalation and dose expansion study in participants with advanced malignancies. Study enrollment is approximately 80 participants. Participants receive oral AMXI-5001, twice daily, as monotherapy. The …

Phase

8.39 miles

Learn More »